IFNAR1 Deficiency Impairs Immunostimulatory Properties of Neutrophils in Tumor-Draining Lymph Nodes

Tumor-draining lymph nodes (TDLNs) are the first organs where the metastatic spread of different types of cancer, including head and neck cancer (HNC), occurs and have therefore high prognostic relevance. Moreover, first anti-cancer immune responses have been shown to be initiated in such LNs via tumor-educated myeloid cells. Among myeloid cells present in TDLNs, neutrophils represent a valuable population and considerably participate in the activation of effector lymphocytes there. Tumor-supportive or tumor-inhibiting activity of neutrophils strongly depends on the surrounding microenvironment. Thus, type I interferon (IFN) availability has been shown to prime anti-tumor activity of these cells. In accordance, mice deficient in type I IFNs show elevated tumor growth and metastatic spread, accompanied by the pro-tumoral neutrophil bias. To reveal the mechanism responsible for this phenomenon, we have studied here the influence of defective type I IFN signaling on the immunoregulatory activity of neutrophils in TDLNs. Live imaging of such LNs was performed using two-photon microscopy in a transplantable murine HNC model. CatchupIVM-red and Ifnar1-/- (type I IFN receptor- deficient) CatchupIVM-red mice were used to visualize neutrophils and to assess their interaction with T-cells in vivo. We have evaluated spatiotemporal patterns of neutrophil/T-cell interactions in LNs in the context of type I interferon receptor (IFNAR1) availability in tumor-free and tumor-bearing animals. Moreover, phenotypic and functional analyses were performed to further characterize the mechanisms regulating neutrophil immunoregulatory capacity. We demonstrated that inactive IFNAR1 leads to elevated accumulation of neutrophils in TDLNs. However, these neutrophils show significantly impaired capacity to interact with and to stimulate T-cells. As a result, a significant reduction of contacts between neutrophils and T lymphocytes is observed, with further impairment of T-cell proliferation and activation. This possibly contributes to the enhanced tumor growth in Ifnar1-/- mice. In agreement with this, IFNAR1-independent activation of downstream IFN signaling using IFN-λ improved the immunostimulatory capacity of neutrophils in TDLNs and contributed to the suppression of tumor growth. Our results suggest that functional type I IFN signaling is essential for neutrophil immunostimulatory capacity and that stimulation of this signaling may provide a therapeutic opportunity in head and neck cancer patients.

[1]  S. Lang,et al.  The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer , 2022, Cancers.

[2]  D. Schadendorf,et al.  SIRT1‐mediated deacetylation of FOXO3a transcription factor supports pro‐angiogenic activity of interferon‐deficient tumor‐associated neutrophils , 2021, International journal of cancer.

[3]  yang-xin fu,et al.  Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance , 2021, Nature Communications.

[4]  J. Rodríguez-Fernández,et al.  The Actin Cytoskeleton at the Immunological Synapse of Dendritic Cells , 2021, Frontiers in Cell and Developmental Biology.

[5]  A. Bankfalvi,et al.  B-Helper Neutrophils in Regional Lymph Nodes Correlate with Improved Prognosis in Patients with Head and Neck Cancer , 2021, Cancers.

[6]  S. Peters,et al.  GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy , 2021, Cancer Research.

[7]  J. Klode,et al.  Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue , 2019, Science Immunology.

[8]  A. Rivera Interferon Lambda's New Role as Regulator of Neutrophil Function. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  A. Kopitar,et al.  Flow Cytometric Determination of Actin Polymerization in Peripheral Blood Leukocytes Effectively Discriminate Patients With Homozygous Mutation in ARPC1B From Asymptomatic Carriers and Normal Controls , 2019, Front. Immunol..

[10]  Subbaya Subramanian,et al.  Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors , 2019, bioRxiv.

[11]  R. Alon,et al.  Stable contacts of naïve CD4 T cells with migratory dendritic cells are ICAM-1-dependent but dispensable for proliferation in vivo , 2019, Cell adhesion & migration.

[12]  D. Schadendorf,et al.  NAMPT signaling is critical for the proangiogenic activity of tumor‐associated neutrophils , 2018, International journal of cancer.

[13]  Z. Granot,et al.  Neutrophil, quo vadis? , 2017, Journal of leukocyte biology.

[14]  J. Buer,et al.  Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth , 2017, Nature Communications.

[15]  Amy R. Peck,et al.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. , 2017, Cancer cell.

[16]  S. Lang,et al.  The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils , 2016, Front. Immunol..

[17]  B. Becher,et al.  BAFF-secreting neutrophils drive plasma cell responses during emergency granulopoiesis , 2016, The Journal of experimental medicine.

[18]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[19]  W. Hara,et al.  Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas , 2016, Cancer.

[20]  B. Schilling,et al.  Type I IFNs induce anti‐tumor polarization of tumor associated neutrophils in mice and human , 2016, International journal of cancer.

[21]  Z. Granot,et al.  Distinct Functions of Neutrophil in Cancer and Its Regulation , 2015, Mediators of inflammation.

[22]  F. Klawonn,et al.  The lack of type I interferon induces neutrophil‐mediated pre‐metastatic niche formation in the mouse lung , 2015, International journal of cancer.

[23]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[24]  A. Waisman,et al.  Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes , 2015, Nature Methods.

[25]  J. Jonkers,et al.  IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis , 2015, Nature.

[26]  A. Stiff,et al.  Investigations of Interferon-Lambda for the Treatment of Cancer , 2015, Journal of Innate Immunity.

[27]  S. Singhal,et al.  Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. , 2014, The Journal of clinical investigation.

[28]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[29]  S. Singhal,et al.  Neutrophils recruit regulatory T‐cells into tumors via secretion of CCL17—A new mechanism of impaired antitumor immunity , 2014, International journal of cancer.

[30]  F. Belardelli,et al.  Type I Interferons as Regulators of Human Antigen Presenting Cell Functions , 2014, Toxins.

[31]  S. Weiss,et al.  CXCR2‐mediated tumor‐associated neutrophil recruitment is regulated by IFN‐β , 2014, International journal of cancer.

[32]  R. Weichselbaum,et al.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. , 2014, Cancer cell.

[33]  Paul Kubes,et al.  Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. , 2013, The Journal of clinical investigation.

[34]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[35]  André Scherag,et al.  Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease , 2011, International journal of cancer.

[36]  D. Baker,et al.  Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. , 2011, Blood.

[37]  L. Norton,et al.  Tumor entrained neutrophils inhibit seeding in the premetastatic lung. , 2011, Cancer cell.

[38]  A. Chevailler,et al.  CCR7 is involved in the migration of neutrophils to lymph nodes. , 2011, Blood.

[39]  Thijs J. Hagenbeek,et al.  Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes , 2010, Proceedings of the National Academy of Sciences.

[40]  A. Melcher,et al.  Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. , 2010, Cancer research.

[41]  D. Ganea,et al.  IFN-β Inhibits Dendritic Cell Migration through STAT-1–Mediated Transcriptional Suppression of CCR7 and Matrix Metalloproteinase 9 , 2010, The Journal of Immunology.

[42]  S. Weiss,et al.  Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. , 2010, The Journal of clinical investigation.

[43]  A. D. Torre,et al.  Antitumor activity of Type I and Type III interferons in BNL hepatoma model , 2010, Cancer Immunology, Immunotherapy.

[44]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[45]  K. Rajewsky,et al.  Novel Reporter Mouse Reveals Constitutive and Inflammatory Expression of IFN-β In Vivo1 , 2009, The Journal of Immunology.

[46]  T. Pandita,et al.  Absence of IFN-β Impairs Antigen Presentation Capacity of Splenic Dendritic Cells via Down-Regulation of Heat Shock Protein 701 , 2009, The Journal of Immunology.

[47]  B. Elzey,et al.  Preclinical models of HPV+ and HPV− HNSCC in mice: An immune clearance of HPV+ HNSCC , 2009, Head & neck.

[48]  B. Pollock,et al.  Risk for Depression During Interferon-Alpha Treatment Is Affected by the Serotonin Transporter Polymorphism , 2009, Biological Psychiatry.

[49]  Michael Loran Dustin,et al.  Cell adhesion molecules and actin cytoskeleton at immune synapses and kinapses. , 2007, Current opinion in cell biology.

[50]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[51]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[52]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[53]  Michael Loran Dustin,et al.  ICAM-1 co-stimulates target cells to facilitate antigen presentation. , 2005, Current opinion in immunology.

[54]  C. Harding,et al.  Neutrophils Process Exogenous Bacteria Via an Alternate Class I MHC Processing Pathway for Presentation of Peptides to T Lymphocytes1 , 2001, The Journal of Immunology.

[55]  O. Majdic,et al.  Neutrophil Granulocyte–committed Cells Can Be Driven to Acquire Dendritic Cell Characteristics , 1998, The Journal of experimental medicine.

[56]  A. Lewis-Antes,et al.  IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex , 2003, Nature Immunology.